Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cycle times of B-OM results are getting faster. Cycle 1= 27 days, cycle 2 = 21 days, cycle 3 = 4 days (submitted to fda 12/13/18 returned to ipix 12/17/18.).
Should hear of something soon.
https://clinicaltrials.gov/ct2/show/results/NCT02324335?term=innovation+pharmaceuticals&draw=1&rank=3
"My tingling leg says get up early tomorrow."
Any chance somebody just told you it's raining?
Or, perhaps his p results can not be with-held and gravity is sharing the results?:0
"Couldn't imagine Pfizer or any important company partnering with IPIX when they can pick up the scraps at auction."
Perhaps, but there is always a chance that they actually had ~cda's(not all for one product as I understand it). If the phase 2 data, as well as feedback from bp's as a result of the eop2b meeting with the fda is encouraging to any of them, then I would think the talking would ramp up.
To answer your first question-"Can you confirm 20 CDA's were signed?"- no I can't. I also believe ipix has too much exposure to lie. They hired a notable attorney(former Massachusetts U.S Attorney) to represent them vs mako, multiple articles in the Boston Business Journal(gotta wonder why no follow-up by them).
I don't know, I hope this doesn't end up Incineration Pharmaceuticals(unless, of course, the shorts get burned(have a tough time believing people play short with a 10 cent stock)).
seriously?
What a joke!
JTO,
You're right. Both are hysterical.
They've run three products, B for OM, K for ovarian cancer, and P for psoriasis through clinical trials in the states. B is crrently front and center and voted most likely to succeed. K, after a 2 person ph 2 to has been declared a success-await next move. Regarding P, sounds like it's taking a nap (at best). P could have tripped up somewhere along the trial and now considered "Abby Normal".
Beware blazing saddles.
p.s ABBISSI UP was done in Italy wasn't it? Has fda/clinicaltrials been involved at all with it to date? Does it matter?
LR,
In response to your statement " don't think that "some additional lab or trial work needed to be done" meets that exception. It seems the statement even anticipates in their e.g. that a change to sachet packaging would be part of the initial meeting. If some kind of bridging trial was needed it sounds like they would make that clear at the original meeting. I get the sense that they would really rather not have a second meeting during that 30 day period, certainly not one that involves the full staff or any broad go/no-go type decisions."
Regarding the highlighted portion of your above quote, might it be possible they(ipix) request a 3 arm ph 3, rather than a bridging trial(sachets) followed by ph3, meaning they propose the ph3 for B-OM trial be comprised of 3 arms- the 2 arms of 2b(placebo and B swish and spit) as well as a third arm, the sachets?
That's how I would do it(but I'm an engineer in the construction field).
I feel the cartoon, linked below, is more humourous than refereneces of going over Niagra Falls in a barrel, though the latter(the fallas) is likely more accurate to date for ipix investors (at least the buyer got a swing in the end).
http://www.projectcartoon.com/cartoon/46980
I'll call it a nice week based upon(sorry forgot the poster, tryz, heretoday, BooDog,someone elese?-sorry) that the clinicaltrials(ct) site was updated to show ipix responed to ct's 12/5/18 response to ipix'x initial 11/14/18 response to ct(ping- pong anyone). That's definetly good.
The sp performance for the week is not so "nice". Monday close=.16, Friday close=.145
"Celgene is down 33% on the year, Revlimid makes up about 63% of Celgene's revenue. A huge moneymaker for the company, but they are going to be facing generic competition as soon as 2022, and there are multiple generic competitors. Wouldn’t this Big Pharma love to have a couple of new blockbuster drugs like Brilacidin and Prurisol…My money’s on Celgene for Partnership"
Interesting post. Who knows? U-Penn could likely buy back what they sold to ctix, via their endowment funds, me thinks.
Too bad ipix hasn't been able to get off the ground.
we'll see.
George, we are at 16 cents, $0.16/share. What's a fair share price, and where is it heading? tis a rheatorical question
George,
"May all the good things of life be yours now and throughout the coming year"
Likewise to you, and all, whichever religion one celebrates(perhaps none at all).
p.s even Festivus, from this classic
Call Bertolino at his listed extension. Easy peasey(how ever it's spelled)
Crickets, at this point(response wise).
Why?
All,
Please, don't get me wrong, I do hope for the best.
I hope SOME(all) of you enjoy the following.
"It's always calmest while being in the "Eye of the Storm"..."
Quite true, when speaking of hurricanes. I think the last three years have subjected ipix investors to a horrendous storm. Look at a chart, and argue otherwise.
Would you rather have General John Kelly, or 5 defermnent Donald (college/bone spurs, this country clubber has traveled more miles on a country club course than many enlisted men and woman)((bone spurs-seriously?)) Trump, covering you? I'll take the former over the latter. JMO. Perhaps the military is corrupt, I think not. That's(character of Kelly vs. the likes of Trump) the territory we are now in, imho, both here, and there.
frrol,
How does one apply the words"most definitely" to your quoted statement "We will likely hear...."
Since when does likely mean definite? Please explain.
LR,
"If you're right about the $2M/qtr rate of spending...and I don't think it's at all appropriate for a developing company that needs to run clinical trials to expect a smooth run rate... not only will the MFO have to be very accommodating but the Company will also need another source of funds before a year is up."
I agree 100%(Not sure why I put it that way as I know there is no perfect engine(machines, nor humans, are 100% efficient), must be something ringing in my ears)).
I thought mgmt's estimation of annual costs was~ $12M/year-$3M/qtr. $2M/qtr would mean a burn rate of $8M/yr. I do not recall seeing a figure as low as that. I may have missed it.
Perhaps the poster you quoted can provide the source?
Another offering?
idk
LR,
Good find, thanks for posting. If I read it correctly, it appears the National Library of Medicine(NLM) returned it to ipix on 11/14/18 and ipix responed the same day(11/14/18).
"The FACTS have not changed:"
Something has shifted causing a significant change in the share price.
Statements are an historical fact, which is what you beleaguer us with, are they justifiable?
DUP,
Over the years I have spoken with 5 people at ctix/ipix. LE,KM, ABM, NT, and HK(wasn't aware he was associated with the company when he picked up the horn).
AB is not included in the company contact directory(at least the last time I tried last month(when HK picked up)) as far as I can tell, or have experienced. Were you able to reach Dr B directly via company supplied contacts, or via some other route?
Thx
LR,
From the following link- https://clinicaltrials.gov/ct2/about-studies/glossary
Note words high lighted appear in both fefinition, words in bold type appear only one of the definitions.
Primary completion date
The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "estimated" primary completion date is the date that the researchers think will be the primary completion date for the study.
Study completion date
The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "estimated" study completion date is the date that the researchers think will be the study completion date.
Just back from T-Day gathering.
Haven't read the email directly, other than from a poster here. Sounds encouraging.
"You are Right and I’m pretty sure all of this will enfold shortly..."
I hope you meant "unfolds shortly", meaning spread. Enfold is to fold in(upon itself) surround, etc (I think).
Never the less, I hope I got your point(any linguists out there?)
Hope all had an enjoyable T-Day.
"...that a nefarious and malignant cabal is trying to destroy IPIX..."
What do have against Cabal?
"Capitulation does happen,but rememberBuffet said Buy when there is blood in the street"
Please double check your facts- that quote is credited to some fella named Rothschild.
https://www.investopedia.com/articles/financial-theory/08/contrarian-investing.asp
".. to be made public as it has been discussed that the FDA only releases BTD results semi-annually...”
Where did he pull that rabbit from?
https://www.focr.org/breakthrough-therapies through 11/16/18
semi-annually-ha-ha
"Could this increase Pfizer/Merck's interest in Kevetrin?"
Did either ever express any interest? Please, tell.
"Five months latter and no clarification extremely disappointing and very poor budgeting from a cpa, not a leo basher but facts speak for themselves.
That p/r led most to believe results would be announced soon. Start of the summer slaughter that has yet to be reversed."
Yeah, I think most have relinguished faith in "the" CEO's words.
Polly want a cracker?
Maura Healey can be a pit bull.
"What's confusing to most are the BTD comments from the Aspire rep believing BTD stood a great chance by 9/30? Same goes for P data and OM partner. The up-listing fumble was outdone by the 3 milestone deadline."
At the very least we are coming in on one wing and a prayer with eop2 bom meeting. Hopefully(grand hope), the ph2b results restart an engine, and the k gerbil wheel provides some useful, ancillary power.
idk
Cognition,
To my mind, a day is a day unless defined otherwise. Business and government often distinguish the difference. Perhaps the FDA has not the intellect to distinguish the difference, but, based on thier own site, I would guess the sand now sits at the bottom of the sand glass as it's been 62 days since 9/20/18.
Worth no more than a dime/share in your estimation?
"I believe Leo can't buy the stock since he is negotiating a deal. I believe it would be called insider trading." Perhaps you are right, but this company was founded in 2005. Why, do you summize, has he NEVER bought on the open market?
"If this company fails he will miss out on being an extremely wealthy man." Are you suggesting he has not personally done well financially with this company to date?
"Since the FDA has scheduled a meeting with IPIX, they must feel that there is something important to discuss pertaining to going forward to eventually bringing the drug to market." I would love to know the date of that scheduled meeting.
Reminds me of this rags to riches story:).
Yeah, seen that resume many times. The one question I always think apon reading it is, what was he doing prior to his 15 years of domestic and global drug development and management. I believe he's ~63 years old. 63-15= 48. Out of scholl likely between the age of 25 to 28 years old. What was he doing from ~ 1978-1979 to 2003?
Don't get me wrong, I believe he's qualified, just think his history could use a bit more clarity.
"Dr. Bertolino serves as President and Chief Medical Officer at Innovation Pharmaceuticals. Dr. Bertolino is a leading pharmaceutical dermatology executive with over 15 years of domestic and global drug development and management experience."
"If Leo paid the CRO out of his own pocket, it would have to be another loan. Then the complaint would be the CEO gave himself another sweetheart deal. There is no winning for him under the current attacks against the company. Anything and everything is twisted and spun as being wrong."
For the most part his words have proven worthless, and the words of his primary(no questions allowed) supporters on this board are worth even less than his.
Blue Fin,
Pardon my ignorance, but how do you know "MM'S keep smacking it down with short sales of cheap shares, not for much longer."? Please explain the system you know.
Thanks,
kfc
Why not offer to pay the cro In shares?
"Go look at the K pre-clinical data."
And that pre-clinical work was performed by who.... Kard?
A few years ago...
BP: Those pre-clinical results are quite impressive, can we speak with them(Kard).
ipix; No problem, they rent space from us right down the hall. Listen fellas, our meeting was 75 minutes long, 15 minutes longer than the maximum time projected. Kard is a couple doors down the hallway and is the only office with anyone in it. Ask for my son, Elliot Ehrlich or his co worker Mr. Menon. I'd join you but it's lunch time and the tummy is rumbling. I'm going across the street for a happy meal at the golden arches.
BP: ?
"Our first Phase 3 drug trial. I think some of us need to stop and think about that. Very exciting stuff. We just need to get that partner to pay for it."
Ipix's first phase 3 potential was absssi I believe, but was put on hold due to ph 3 projected costs. They decided to pursue less costly trials, and, as we see today, are collecting road side cans for money.
Very exciting stuff for sure. They appear to have sucessfully screwed anyone who has given them an ear, and money. Shareholders-ha-ha ha, Aspire apparently despises them, and the MFO(multiy family organazation I suspect is made up of ehrlich's and menon's mainly.
To counter boodog's "getr done leo", Massachusetts attorneys are happy he set up shop here, "we'll get you leo".
I am long(wasn't keen enough to bail out long ago, and trusted what the CEO STATEEE, EMAILED, BLOGED, PUBLISHED, AND FILED.
Forward looking statements provide a weak wall of protection against a good lawyer.
Jhawker,
Thanks for the post. Times are changing.